| 2021 | 2022 | 2023 | 2024 (projected) | Total Revenue | 80.1M | 81.8M | 94.0M | 98.7M | Depreciation And Amortization | 12.0M | 3.3M | 3.8M | 3.1M |
Ownership Breakdown
| Retail Investors47.58% | Institutions51.21% |
| Retail Investors | 47.58 | |
| Insiders | 1.22 | |
| Institutions | 51.2 |
Will Theratechnologies (USA Stocks:THTX) turn things around in November?
 | By Aina Ster | Macroaxis Story |
Considering Theratechnologies' recent diluted EPS of -0.13 and a profit margin showing a loss of 8%, potential investors might want to approach with caution until there's clearer evidence of a financial turnaround.
Key Takeaways
Theratechnologies is currently priced at $5.30 per share, suggesting it might be undervalued with moderate growth expectations. The stock has a beta of 1.59, indicating it carries a higher risk compared to the broader market. This means that if the market rises, Theratechnologies is likely to outperform; however, it could underperform if the market declines. Presently, the stock has a negative expected return of -0.21%. It's important to review the company's coefficient of variation, value at risk, and the interplay between value at risk and the rate of daily change. These factors will help determine whether Theratechnologies' past performance might be replicated in the future.Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Raphi Shpitalnik
In the realm of investing, patience can be a virtue, and for those eyeing Theratechnologies, November might be a test of that patience. The company, trading on NASDAQ under THTX, is grappling with a few financial hurdles. With a profit margin at a negative eight percent and net interest income showing a loss of 10.6 million, the road to recovery seems challenging. However, there are glimmers of hope. The EPS estimate for next year stands at a promising 0.13, indicating potential profitability on the horizon. As a player in the biotechnology sector, Theratechnologies operates in an industry known for its volatility but also its capacity for breakthroughs. With only one analyst buy recommendation and a lowest estimated target price of 16.15, investors might be weighing the risks against the potential rewards. As always, thorough research and a clear understanding of your investment goals are key when considering such opportunities. Currently, Theratechnologies' Price-to-Earnings Growth (PEG) Ratio remains relatively stable compared to last year. However, Days of Payables Outstanding is expected to increase to 122.30 in 2024, while the Market Cap might slightly decrease to just over $35.6 million. In this analysis, we'll explore whether Theratechnologies shares are fairly valued as we approach November. Additionally, we'll examine key indicators that investors should keep an eye on this month.The performance of Theratechnologies in the marketplace will significantly impact your decision to invest in its stock. Revenue growth, profitability, competitive positioning, management quality, and industry trends can influence Theratechnologies' stock prices. When investing in Theratechnologies, there are several factors to consider and potential outcomes to expect. As a company performs well, its stock price may increase, allowing investors to benefit from price appreciation. However, Theratechnologies Stock can experience significant price fluctuations due to market conditions, economic factors, industry trends, or company-specific news. This is why investing in stocks such as Theratechnologies carries risks, including the potential for capital loss. Stock prices can decline, and investors may incur losses if they sell shares at a lower price than their initial investment.
Watch out for price decline
Please consider monitoring Theratechnologies on a daily basis if you are holding a position in it. Theratechnologies is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Theratechnologies stock to be traded above the $1 level to remain listed. If Theratechnologies stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How important is Theratechnologies's Liquidity
Theratechnologies financial leverage refers to using borrowed capital as a funding source to finance Theratechnologies ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Theratechnologies financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Theratechnologies' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Theratechnologies' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Theratechnologies's total debt and its cash.
Theratechnologies Gross Profit
Theratechnologies Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Theratechnologies previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Theratechnologies Gross Profit growth over the last 10 years. Please check Theratechnologies' gross profit and other fundamental indicators for more details.
Detailed Perspective On Theratechnologies
Theratechnologies shows a total of 45.98 Million outstanding shares. Over half of Theratechnologies' outstanding shares are owned by institutional holders. These institutional holders are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
In the stock market, patience can often be a virtue, especially for investors eyeing Theratechnologies. With a market capitalization of $56.23 million and a price-to-sales ratio of 0.68x, the company is navigating a challenging landscape in the biotechnology sector. Despite reporting a net income loss of $24 million, there is a glimmer of hope with an EPS estimate of $0.13 for next year, suggesting potential for recovery. As November approaches, investors will be keen to see if Theratechnologies can leverage its $36.46 million in cash and equivalents to stabilize and potentially rebound. The company's fiscal year end in November might provide a pivotal moment for assessing its strategic direction and financial health..
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Aina Ster do not own shares of Theratechnologies. Please refer to our Terms of Use for any information regarding our disclosure principles.